Ocugen is not chasing single-gene fixes. Instead, its “modifier gene therapy” approach aims to activate entire networks of healthy genes, potentially treating multiple inherited retinal diseases regardless of the exact mutation behind them. The company is now laying out a clear timetable to bring three such therapies to the US market, with biologic license applications (BLAs) planned across the next three years. The ambition is matched by Wall Street’s price target: a consensus of €10.01 per share, implying a gain of more than 670% from the stock’s recent level around €1.30.
Three Programs, Three Different Timelines
The lead candidate, OCU400, targets retinitis pigmentosa. Ocugen expects to file its BLA next year, after topline data from a pivotal study arrives in the first half of 2027. A second program, OCU410ST for Stargardt disease, could follow a similar path, with a registration-enabling study potentially supporting a submission by mid-2027.
The third and most ambitious program, OCU410, treats geographic atrophy — the late-stage form of dry age-related macular degeneration. That therapy is now entering Phase 3 testing in an adaptive trial of fewer than 300 patients, designed in consultation with regulators in both the US and Europe. Ocugen expects the BLA for OCU410 by 2028, citing the size and complexity of the study as reasons for the later timeline.
So far, Phase 2 data for OCU410 have shown a roughly 33% reduction in lesion growth at the mid-dose level, with preliminary 12-month results from the ArMaDa study confirming statistical significance and a clean safety profile. The company says none of its three programs have produced serious drug-related adverse events to date.
A Market Gap of More Than 670%
If the pipeline succeeds, the addressable patient populations are substantial. Ocugen estimates over 100,000 retinitis pigmentosa patients in the US alone, roughly 50,000 Stargardt patients, and between 2 million and 3 million people in the US and EU living with geographic atrophy in its advanced form. Those numbers help explain why analysts have set an average price target of €10.01, far above the current market price.
Should investors sell immediately? Or is it worth buying Ocugen?
But the stock tells a different story. At a market capitalisation of roughly €436 million, Ocugen remains a speculative bet. The shares have gained about 10% since the start of the year and 24% over the past 30 days, yet they still trade around 45% below the 52-week high of €2.35 hit in March. The 52-week low of €0.82, set in August 2025, shows how far the stock can swing in either direction.
Volatility That Rivals Crypto
Annualised 30-day volatility stands at 67.28% — a figure more common among cryptocurrency assets than clinical-stage biotechs. Investors are pricing in the binary nature of late-stage trials: a single negative readout could erase value just as quickly as a positive one could multiply it. The recent rally, while encouraging, has not pushed the stock into overbought territory. The relative strength index sits around 55, a neutral reading that leaves room for further upward movement — or a pullback.
Technically, the shares have climbed 8.5% above their 50-day moving average of €1.20 but remain just below the 200-day average of €1.32. This places the stock in a tight range that often precedes a more decisive move once a catalyst arrives.
What Comes Next
The next major milestone is the OCU400 topline data, expected in the first half of next year. That readout will test not only the safety and efficacy of the therapy itself but also the viability of Ocugen’s modifier gene therapy platform — a technology that, if validated, could open up multiple billion-dollar markets. Until then, the stock will likely continue oscillating between scientific hope and financial caution, with each news cycle capable of rewriting the valuation entirely.
Ad
Ocugen Stock: Buy or Sell?! New Ocugen Analysis from July 13 delivers the answer:
The latest Ocugen figures speak for themselves: Urgent action needed for Ocugen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 13.
Ocugen: Buy or sell? Read more here...
